藥物發現市場規模、佔有率、成長分析，依藥物類型、技術、製程、最終用戶、地區產業預測，2024-2031

Drug Discovery Market Size, Share, Growth Analysis, By Drug Type (Small Molecule Drugs, Biologic Drugs), By Technology (High Throughput Screening (HTS), Pharmacogenomics), By Process, By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年12月20日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球藥物發現市場規模為957億美元，從2023年的1020.2億美元成長到2031年的1701.1億美元，年複合成長率預計為6.6%。

在疾病流行、技術進步和個人化醫療需求不斷成長的推動下，全球藥物發現市場預計將顯著成長。我猜創新的研究和開發舉措側重於新的藥物標靶和有效的治療方法，採用結合基因組學、蛋白質組學和計算生物學的跨學科方法來闡明疾病機制並簡化藥物發現。此外，利用高性能篩檢、人工智慧、巨量資料分析等最尖端科技將顯著提高藥物開發的效率和成功率。隨著對精準醫療和標靶治療的重視，市場預計在未來幾年將顯著擴大，使該公司成為醫療行業的重要參與企業。

Pfizer Inc.
Novartis AG
Merck & Co., Inc.
Johnson & Johnson
Roche Holding AG
Sanofi SA
GlaxoSmithKline plc
AstraZeneca plc
Bristol-Myers Squibb Company
Eli Lilly and Company
AbbVie Inc.
Amgen Inc.
Bayer AG
Takeda Pharmaceutical Company Limited
Gilead Sciences, Inc.
Biogen Inc.
Boehringer Ingelheim GmbH
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
Novo Nordisk A/S

結論和建議

簡介目錄

Product Code: SQMIG35H2100

Global Drug Discovery Market size was valued at USD 95.70 billion in 2022 and is poised to grow from USD 102.02 billion in 2023 to USD 170.11 billion by 2031, growing at a CAGR of 6.6% during the forecast period (2024-2031).

The Global Drug Discovery market is poised for substantial growth, fueled by rising disease prevalence, technological advancements, and a heightened demand for personalized medicine. Innovative R&D initiatives are focusing on novel drug targets and effective therapeutics, with an interdisciplinary approach that incorporates genomics, proteomics, and computational biology to unravel disease mechanisms and streamline drug discovery. Furthermore, the utilization of cutting-edge technologies such as high-throughput screening, artificial intelligence, and big data analytics significantly improves the efficiency and success rates of drug development. As the emphasis on precision medicine and targeted therapies intensifies, the market is set for remarkable expansion in the upcoming years, positioning it as a key player in the healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Drug Discovery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Drug Discovery Market Segmental Analysis

Global Drug Discovery Market is segmented by drug type, technology, process, end user and region. Based on drug type, the market is segmented into small molecule drugs and biologic drugs. Based on technology, the market is segmented into high throughput screening (HTS), pharmacogenomics, combinatorial chemistry, nanotechnology and other. Based on process, the market is segmented into target selection, lead optimization and hit-to-lead identification. Based on end user, the market is segmented into pharmaceutical companies, contract research organizations (CROs), academic and research institutes and other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Drug Discovery Market

A key driver of the Global Drug Discovery market is the escalating prevalence of chronic and infectious diseases. The growing rates of conditions such as cancer, cardiovascular diseases, and various infectious illnesses have intensified the demand for innovative and effective pharmaceutical solutions. This surge in disease incidence compels pharmaceutical companies and research institutions to prioritize investment in drug discovery and development efforts, accelerating the creation of new treatments and therapies to address these pressing health challenges. As a result, the landscape of drug discovery is becoming increasingly vital in the quest for improved healthcare outcomes and enhanced patient well-being worldwide.

Restraints in the Global Drug Discovery Market

The Global Drug Discovery market faces significant restraints primarily due to the high costs and the lengthy nature of the drug development process. The journey from drug discovery to market approval is intricate and resource-intensive, necessitating considerable investments in research, clinical trials, and navigating regulatory requirements. This complexity, coupled with stringent safety and efficacy standards, extends development timelines and inflates overall expenses. As a result, these factors can hinder the accessibility and affordability of innovative medications, creating challenges for stakeholders involved in the drug discovery process and potentially impacting the market's growth trajectory.

Market Trends of the Global Drug Discovery Market

In the Global Drug Discovery market, a significant trend is the escalating integration of artificial intelligence (AI) and machine learning (ML) technologies, catalyzing a transformative shift in the drug development landscape. These innovative technologies facilitate the rapid analysis of extensive biological datasets, allowing for precise identification of drug-target interactions and streamlined workflows. AI-driven virtual screening and molecular modeling not only enhance the efficiency of drug candidate identification but also reduce overall costs and timelines associated with the drug discovery process. As a result, this trend is poised to improve success rates in clinical trials and foster the emergence of novel therapeutics, ultimately reshaping the pharmaceutical industry's approach to drug development.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Driver & Opportunities
- Restraints & Challenges
Porters Analysis & Impact
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Patent Analysis

Global Drug Discovery Market Size by Drug Type & CAGR (2024-2031)

Market Overview
Small Molecule Drugs
Biologic Drugs

Global Drug Discovery Market Size by Technology & CAGR (2024-2031)

Market Overview
High Throughput Screening (HTS)
Pharmacogenomics
Combinatorial Chemistry
Nanotechnology
Other

Global Drug Discovery Market Size by Process & CAGR (2024-2031)

Market Overview
Target Selection
Lead Optimization
Hit-to-Lead Identification

Global Drug Discovery Market Size by End User & CAGR (2024-2031)

Market Overview
Pharmaceutical Companies
Contract Research Organizations (CROs)
Academic and Research Institutes
Other

Global Drug Discovery Market Size & CAGR (2024-2031)

North America (Drug Type, Technology, Process, End User)
- US
- Canada
Europe (Drug Type, Technology, Process, End User)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific (Drug Type, Technology, Process, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
Latin America, (Drug Type, Technology, Process, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Type, Technology, Process, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Incorporated
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments